- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01021358
A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax).
December 16, 2010 updated by: Abbott
A Phase 1 Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of ABT-263 (Navitoclax)
This is a single dose, open-label, single or multiple center study to determine the interaction of ketoconazole with ABT-263 in approximately 12 subjects with cancer.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
12
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
San Antonio, Texas, United States, 78229
- Site Reference ID/Investigator# 25068
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 18 years of age or older.
- Has a non-hematologic malignancy (radiographic, histologic, or cytologic confirmation), or hematologic malignancy (histologic or cytologic confirmation) that is either: relapsed or refractory to standard therapy, failed at least one prior therapy or no known effective therapy exists.
- In the investigator's opinion, the subject's life expectancy is at least 90 days.
- If clinically indicated, (e.g., subjects over the age of 70) subjects must have documented brain imaging (MRI or CT) negative for subdural or epidural hematoma within 28 days prior to the first dose of study drug.
- Subjects with brain metastases must have clinically controlled neurologic symptoms, defined as surgical excision and/or radiation therapy followed by 21 days of stable neurologic function and no evidence of CNS disease progression as determined by CT or MRI within 21 days prior to the first dose of study drug.
Exclusion Criteria:
- History of or is clinically suspicious for cancer-related central nervous system (CNS) disease.
- Has undergone an allogeneic stem cell transplant.
- Has an underlying, predisposing condition of bleeding or currently exhibits signs of bleeding.
- Has active peptic ulcer disease or other hemorrhagic esophagitis/gastritis.
- Has active immune thrombocytopenic purpura or a history of being refractory to platelet transfusions (within 1 year prior to the first dose of study drug).
- Significant history of cardiovascular disease (e.g., MI, thrombotic or thromboembolic event in the last 6 months), renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, or hepatic disease. Female subject is pregnant or breast-feeding.
- History of or an active medical condition(s) that affects absorption or motility (e.g., Crohn's disease, celiac disease, gastroparesis, short bowel syndrome, etc).
- Exhibits evidence of other clinically significant uncontrolled condition(s) including, but not limited to: active systemic fungal infection; diagnosis of fever and neutropenia within one week prior to study drug administration.
- Received any anti-cancer therapy including chemotherapy, immunotherapy, radiotherapy, hormonal (with the exception of hormones for hypothyroidism or estrogen replacement therapy [ERT], or agonists required to suppress serum testosterone levels [e.g., LHRH, GnRH, etc.] for subjects with prostate cancer
- Currently receiving or requires anticoagulation therapy or any drugs or herbal supplements that affect platelet function.
- Currently receiving or requires anti-fungal treatment or CYP3A inhibitors. In the opinion of the Investigator, the subject is an unsuitable candidate to receive ABT-263.
- History of or is clinically suspicious for cancer-related central nervous system (CNS) disease.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm A (ABT-263 and Ketoconozole)
|
Subjects will be dosed with ABT-263, then dosed with ABT-263 in combination with Ketoconazole.
Subjects will be dosed with ABT-263, then dosed with ABT-263 in combination with Ketoconazole.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine the effect of ketoconazole on the pharmacokinetics of ABT- 263.
Time Frame: Weekly
|
Weekly
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine the safety of ABT-263 when administered alone and in combination with Ketoconazole in these patients.
Time Frame: Daily
|
Daily
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2010
Primary Completion (Actual)
October 1, 2010
Study Registration Dates
First Submitted
November 25, 2009
First Submitted That Met QC Criteria
November 25, 2009
First Posted (Estimate)
November 30, 2009
Study Record Updates
Last Update Posted (Estimate)
December 20, 2010
Last Update Submitted That Met QC Criteria
December 16, 2010
Last Verified
December 1, 2010
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Leukemia, Lymphoid
- Leukemia
- Leukemia, B-Cell
- Leukemia, Lymphocytic, Chronic, B-Cell
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Hormone Antagonists
- Antifungal Agents
- Steroid Synthesis Inhibitors
- 14-alpha Demethylase Inhibitors
- Ketoconazole
- Navitoclax
Other Study ID Numbers
- M10-957
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma
-
Novartis PharmaceuticalsBristol-Myers SquibbRecruitingNon-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone LymphomaUnited States, Germany, Italy, Korea, Republic of, Spain, Singapore, China, Japan, Australia
-
Marcela V. Maus, M.D.,Ph.D.RecruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Non-Hodgkin Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Non-hodgkin Lymphoma | High-grade B-cell Lymphoma | Grade 3b Follicular Lymphoma | Relapsed Non-Hodgkin LymphomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell... and other conditionsUnited States
-
BioNova Pharmaceuticals (Shanghai) LTD.TerminatedFollicular Lymphoma | B-cell Lymphoma | Mantle Cell Lymphoma | Non Hodgkin Lymphoma | Diffuse Large B Cell LymphomaChina
-
Tessa TherapeuticsActive, not recruitingAnaplastic Large Cell Lymphoma | Diffuse Large B Cell Lymphoma | Peripheral T Cell Lymphoma | Extranodal NK/T-cell Lymphoma | Primary Mediastinal Large B-Cell Lymphoma (PMBCL)United States
-
Royal Marsden NHS Foundation TrustUnknownMantle Cell Lymphoma (MCL) | Follicular Lymphoma (FL) | Marginal Zone Lymphoma (MZL)United Kingdom
-
AmgenCompletedLymphoma | Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Diffuse Large Cell Lymphoma | Low Grade Lymphoma
-
IGM Biosciences, Inc.ADC Therapeutics S.A.Active, not recruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | DLBCLUnited States, Korea, Republic of, Spain, France, Australia, Czechia, Italy
-
BeiGeneCompletedCutaneous T-cell Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Adult Nasal Type Extranodal NK/T-cell Lymphoma | Anaplastic Large Cell Lymphoma, ALK-Positive | Extranodal NK/T-cell Lymphoma, Nasal Type | Peripheral T Cell Lymphoma | Extranodal NK/T-cell Lymphoma | Peripheral... and other conditionsChina, Taiwan, Germany, France, Canada, Italy
-
Reid Merryman, MDGenentech, Inc.RecruitingFollicular Lymphoma | Marginal Zone Lymphoma | Indolent Non-hodgkin LymphomaUnited States
Clinical Trials on ABT-263
-
Kathleen LudwigAvailableRelapsed Childhood ALL | Relapsed Childhood Lymphoblastic LymphomaUnited States
-
AbbVie (prior sponsor, Abbott)Genentech, Inc.CompletedSmall Cell Lung Carcinoma | Small Cell Lung CancerUnited States, Canada, United Kingdom
-
Centre Francois BaclesseARCAGY/ GINECO GROUP; French Cancer Research Hospital ProgramCompletedPlatinum-resistant or Refractory Ovarian CancerFrance
-
AbbVieNo longer availableMyelofibrosis | Lymphoblastic Lymphoma | Acute Lymphocytic Leukemia (ALL)United States
-
AbbVie (prior sponsor, Abbott)CompletedChronic Lymphocytic LeukemiaUnited States, Australia, Israel, Poland, Ukraine
-
AbbottGenentech, Inc.CompletedHealthy Female SubjectsUnited States
-
National Cancer Institute (NCI)TerminatedRefractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Unresectable Solid Neoplasm | Recurrent Lung Small Cell Carcinoma | Stage IIIA Lung Small Cell Carcinoma AJCC v7 | Stage IIIB Lung Small Cell Carcinoma AJCC v7 | Stage IV Lung Small Cell... and other conditionsUnited States
-
AbbVieGenentech, Inc.CompletedChronic Lymphocytic LeukemiaUnited States, Australia, Germany, United Kingdom
-
AbbottGenentech, Inc.CompletedChronic Lymphocytic Leukemia | Lymphomas | LeukemiasUnited States
-
AbbVieActive, not recruitingMyelofibrosis (MF)United States, Argentina, Australia, Brazil, Bulgaria, Chile, Hungary, Israel, Italy, Japan, Spain, Sweden, Turkey, Korea, Republic of